Kidney

Propanc Biopharma Offers a Novel Way to Stop Cancer

Retrieved on: 
Wednesday, May 11, 2022
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Clinical Trials, Science, Surgery, Biotechnology, FDA, Health, U.S. Securities and Exchange Commission, PPCB, Fats, Differentiable function, Trypsinogen, Brain, B cell, Budget, Prostate, Accounting, Company, Kidney, Patient, Chymotrypsinogen, Security (finance), Breast, Survival, Neoplasm, Metastasis, FDA, Cancer, PRP, OTCQB, Digestion, Enzyme, Cell death, Science, Pancreas, Protein, University of Edinburgh, Research, Growth, Cell, Recurrence, Vaccine, Medical imaging, Pharmaceutical industry

Propanc Biopharma, Inc. (OTCQB: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced a novel way to stop cancer by inducing a process called cell differentiation.

Key Points: 
  • Propanc Biopharma, Inc. (OTCQB: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced a novel way to stop cancer by inducing a process called cell differentiation.
  • Therefore, most common cancer therapies work by taking advantage of the uncontrolled proliferation of cancer cells and kill these cells by targeting the cell division machinery.
  • Differentiation therapy acts not only against cancer cells, but interestingly can turn cancer stem cells (undifferentiated cells) towards completely differentiated (i.e., normal) cells.
  • Propanc Biopharma, Inc. (the Company) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers.

Regulus Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Retrieved on: 
Wednesday, May 11, 2022
Regulus Therapeutics, COVID-19, Drug discovery, Private Securities Litigation Reform Act, IND, Autosomal dominant polycystic kidney disease, Pharmacokinetics, Cyst, Company, Kidney, Food, Safety, PKD1, Toxicology, CA, Patient, MAD, Trial of the century, Autosome, Program, Risk, MicroRNA, FDA, PKD2, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Multimedia, Adult, ADPKD, Disease, Polycystic kidney disease, Liver, U.S. Securities and Exchange Commission, Food and Drug Administration Amendments Act of 2007, SAD, SAN, Chronic kidney disease, Pharmaceutical industry, Regulus

SAN DIEGO, May 11, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) Application for RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), enabling the Company to initiate its planned Phase 1 clinical study of RGSL8429 in healthy volunteers.

Key Points: 
  • The Company will conduct a Phase 1 single-ascending dose (SAD) study in healthy volunteers to assess safety, tolerability and pharmacokinetics of RGLS8429.
  • Excessive kidney cyst cell proliferation, a central pathological feature, ultimately leads to end-stage renal disease in approximately 50% of ADPKD patients by age 60.
  • RGLS8429 is a novel, next generation oligonucleotide designed to inhibit miR-17 and to preferentially target the kidney.
  • Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Better Quality, Lower Costs When Providers and Health Plans Share Financial Risk

Retrieved on: 
Tuesday, May 10, 2022
COVID-19, Medicare, Insurance, AMP, Woman, Health, GLOBE, Kidney, EPO, Breast cancer, PPO, Patient, HMO, Cancer, IHA, Diabetes, Industry, MPH, Association, Program, Risk, General manager, Health insurance, Online shopping, MD

Health plans, providers, purchasers, policymakers, and consumers can use the Atlas to compare quality and cost of care provided to Californians.

Key Points: 
  • Health plans, providers, purchasers, policymakers, and consumers can use the Atlas to compare quality and cost of care provided to Californians.
  • Consistent with prior years, the results released for 2020 show that better care and lower costs typically result when plans and providers share in the financial risk through a capitation arrangement compared to fee-for-service models.
  • Clinical quality composite rates for providers with full financial risk were 6.2 percentage points higher than providers not sharing risk.
  • Total cost of care was 4.9% lower when providers shared financial risk.

UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate Developments

Retrieved on: 
Tuesday, May 10, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Ureter, Birth, Swelling, Kidney, Safety, Urination, Patient Information Advisory Group, Risk, Skin, Female, NMIBC, View, SEC, Trial of the century, Technology, Nausea, Stomach, Pain, Twitter, Water, Perforation, Company, Probability, Patient, Urine, Clinical trial, FDA, Nephrectomy, Sodium bicarbonate, Vomiting, Private Securities Litigation Reform Act, Bone marrow, Medicine, Neoplasm, NDA, Time, Fatigue, UTUC, Clothing, Growth, Man, COVID-19, Transitional cell carcinoma, Abdomen, Fever, Cancer, Blood, Orphan drug, Urinary bladder, Urinary tract infection, Adult, Breast milk, Transitional epithelium, Recurrence, Pharmaceutical industry, Medical imaging, Health insurance, Birth control, Tanning (leather), Phosphorus, Generic drug, Mitomycins, Mitomycin C, Pharmakon—Danish College of Pharmacy Practice

The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.

Key Points: 
  • The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.
  • You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.
  • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO.
  • JELMYTO and UroGen are registered trademarks of UroGen Pharma Ltd.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005510/en/

OmniLife Receives $250,000 SBIR Grant in Support of Transplants for Kids project

Retrieved on: 
Tuesday, May 10, 2022
Technology, Diabetes, Health, Family, Consumer, Surgery, Other Philanthropy, Philanthropy, Software, Managed Care, Other Consumer, Internet, Foundation, Data Management, Linda, Kidney, Communication, Decision-making, Ecosystem, Mortality, Transplant, Algorithm, SBIR, Biostatistics, NIH, Ann Harrison (lung transplant recipient), UPMC, Patient, Doctor of Philosophy, Clinical trial, Program, Investigation, National, Small Business Innovation Research, Machine learning, Benefit corporation, Randomized controlled trial, University, Digestive, UCSF, View, National Institute of Diabetes and Digestive and Kidney Diseases, Research, AI, NIDDK, National Institute, Pharmaceutical industry, Medical device, Computer data storage, Northwestern, Estadio Akron

The grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) will support the Transplants for Kids project, which will use AI / machine learning algorithms to align optimal donor grafts with children awaiting liver transplants.

Key Points: 
  • The grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) will support the Transplants for Kids project, which will use AI / machine learning algorithms to align optimal donor grafts with children awaiting liver transplants.
  • The funded project will confirm the feasibility of a graft selection algorithm that assists the clinical teams with matching candidates with available livers.
  • If successful, hundreds of pediatric patients could benefit from increased access to transplants and decreased wait time.
  • This is the first of two anticipated phases of the project with a total of $2M in expected funding.

Benzinga: Oncocyte Reports It's Ready To Enter The $3.6 Billion Transplant Diagnostics Market In First Half Of 2022

Retrieved on: 
Tuesday, May 10, 2022
Medicare, Nucleic acid thermodynamics, Immune system, Centers for Medicare & Medicaid Services, NEW, Clear, National Institute, LDT, Kidney, NIH, Food, Next Generation, IVD, Criticism of the Food and Drug Administration, PCR, Patient, FDA, US Foods, DNA, CMS, LCD, Center, Advertising, Medicaid, DNA sequencing, Intellectual property, Transplant, IP, Technology, Transplant rejection, National Institutes of Health, Heart, Risk, Acquisition, Multimedia, Dietary supplement, Medical imaging, Dentistry, Health insurance, Pharmaceutical industry

NEW YORK , May 10, 2022 /PRNewswire/ -- The transplant diagnostics market encompasses blood tests, genetic sequencing, and other technology to monitor transplant patients and predict complications to make sure their bodies don't reject new organs or tissue.

Key Points: 
  • NEW YORK, May 10, 2022 /PRNewswire/ -- The transplant diagnostics market encompasses blood tests, genetic sequencing, and other technology to monitor transplant patients and predict complications to make sure their bodies don't reject new organs or tissue.
  • The market was estimated at $3.6 billion in 2019 and is projected to reach $5.5 billion by 2025 as access to lifesaving transplant procedures increases and faster, less complicated, diagnostic tools are developed.
  • Oncocyte Corp.,a company focused primarily on the immune therapy diagnostics market, is setting its sights on the rapidly growing transplant diagnostics market after its acquisition of Chronix Biomedical early last year.
  • The TheraSure Transplant Monitor has not been cleared or approved by the US Food and Drug Administration.

AKEBIA THERAPEUTICS, INC. (NASDAQ: AKBA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Akebia Therapeutics, Inc. (NASDAQ: AKBA)

Retrieved on: 
Tuesday, May 10, 2022
Defendant, Kidney, The Legal 500, NASDAQ, GLOBE, Chronic kidney disease, District court, Securities Exchange Act of 1934, MACE, Akebia, Lists of action films, Patient, Company, Labour government, Anemia, Court, Advertising, Adult, Lists of schools in England, AKBA, Therapy, Program, News, Pharmaceutical industry, Risk management, Security (finance)

Akebia is a biopharmaceutical company that focuses on the development and commercialization of renal therapeutics for patients with kidney diseases.

Key Points: 
  • Akebia is a biopharmaceutical company that focuses on the development and commercialization of renal therapeutics for patients with kidney diseases.
  • Akebias Phase 3 clinical programs for vadadustat include, among others, the PRO2TECT program in NDD-CKD patients with anemia (the PRO2TECT Program).
  • If you purchased AKBA securities, and/or would like to discuss your legal rights and options please visit Akebia Therapeutics, Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Monrol Is Partnering With Telix Pharmaceuticals, Supplying Lutetium nca Lu 177 for the Manufacturing of Clinical Doses for the Phase II STARLITE 2 Study At MSK and Manufacturing Clinical Doses for Telix’s Phase III ZIRCON Trial

Retrieved on: 
Tuesday, May 10, 2022
Science, Other Science, Pharmaceutical, Medical Supplies, Oncology, Health, Hospitals, Clinical Trials, TGA, Safety, Radionuclide, Nivolumab, Degenerative disease, Gallium, CDMO, Carbonic anhydrase, Positron emission tomography, Quality of life, Radiopharmaceutical, Technology, Nuclear medicine, Transport, CFR, ASX, PRRT, Phase, Australian Securities Exchange, Kidney cancer, Oncology, MRI, Patient, NET, Clinical trial, Lung, CA9, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MTR, Breakthrough therapy, LinkedIn, Prostate, Neoplasm, Title 21 CFR Part 11, Histology, Bristol Myers Squibb, PET/CT, Memorial Sloan Kettering Cancer Center, GMP, Movement, Cancer, MSK, Food, Radiation, CT, Diagnosis, Kidney, Prostate cancer, PET, Pharmaceutical industry, Vaccine, Medical imaging, Tax advisor, Animal, Telix, Lutetium

Monrol supplied Lutetium (Lu-177 n.c.a) to Telix Pharmaceuticals to manufacture clinical doses of TLX250 for STARLITE 2 Phase II study.

Key Points: 
  • Monrol supplied Lutetium (Lu-177 n.c.a) to Telix Pharmaceuticals to manufacture clinical doses of TLX250 for STARLITE 2 Phase II study.
  • Clinical doses of Telixs investigational renal cancer companion imaging agent TLX250-CDx (89Zr-DFO-girentuximab) is also produced by Eczacbas Monrol in its Istanbul facility for the Phase III ZIRCON clinical trial.
  • ZIRCON Phase III study (Zirconium Imaging in Renal Cancer Oncology) is an international multi-centre study at 34 sites in Europe, Australia, Turkey, Canada, and the United States.
  • Telixs companion investigational diagnostic imaging agent TLX250-CDx (89Zr-DFO-girentuximab) is the subject of a global Phase III trial recruiting (ZIRCON trial, NCT03849118 ).

Firas A. Adeel, MD is recognized by Continental Who's Who

Retrieved on: 
Tuesday, May 10, 2022
ABIM, University, Music, American Board of Internal Medicine, OH, Chronic kidney disease, Bass, Physician, MBBS, American Society of Nephrology, Patient, Loving Memory, Anderson, Family, Dow University of Health Sciences, Ministry of Health (New South Wales), Outline of health sciences, Dialysis, Kidney failure, MD, Internal medicine, National Kidney Foundation, Continental, Society, Fellow, Kidney, Sodium, American Board of Commissioners for Foreign Missions, Multimedia, Medicine, Dentistry, Nephrology

CINCINNATI, May 9, 2022 /PRNewswire/ -- Firas A. Adeel, MD, is being recognized by Continental Who's Who as a Top Pinnacle Nephrologist in the Medical field and in acknowledgment of his work at Mt.

Key Points: 
  • CINCINNATI, May 9, 2022 /PRNewswire/ -- Firas A. Adeel, MD, is being recognized by Continental Who's Who as a Top Pinnacle Nephrologist in the Medical field and in acknowledgment of his work at Mt.
  • Auburn Nephrology Inc.
    Firas A. Adeel, MD, has six years of experience and currently treats patients at Mt.
  • Dr. Adeel administers dialysis, advocates for home dialysis care, and oversees medical management for kidney transplant patients.
  • He provides personalized treatment plans for his patients, often including medication, specific types of diets, kidney transplants, and dialysis treatments.

Arcellx Announces Publication in Blood Advances of Clinical Results from the Dose Escalation Cohorts of its CART-ddBCMA Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma

Retrieved on: 
Monday, May 9, 2022
Bone, ASCO, U.S. Securities and Exchange Commission, DL2, Multiple myeloma, BCMA, CRS, NASDAQ, Bone density, Bone marrow, Medicine, Securities Exchange Act of 1934, Engineering, Securities Act of 1933, Safety, Food, Time, Regenerative medicine, Kidney, Patient, B cell, American Society of Hematology, Security (finance), Acute myeloid leukemia, Cancer, Diagnosis, Risk, Drug Quality and Security Act, Annual report, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Death, Sumathi Best Television Current Reporting Award, Lymphatic system, Society, MM, Toxic epidermal necrolysis, ORR, Pharmaceutical industry

FOSTER CITY, Calif. , May 9, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the publication of clinical data from its dose escalation cohorts in its ongoing Phase 1 study of CART-ddBCMA for the treatment of patients with relapsed or refractory multiple myeloma (r/r MM). The data were published in Blood Advances, the open-access journal of the American Society of Hematology.

Key Points: 
  • No cases of Grade 3 or higher CRS or ICANS occurred at DL1, the recommended Phase 2 dose.
  • All patients dosed responded to CART-ddBCMA (ORR 100%) and 9/12 (75%) patients achieved CR/sCR.
  • CART-ddBCMA is Arcellx's BCMA-specific CAR-modified T-cell therapy utilizing the company's novel BCMA-targeting binding domain for the treatment of patients with relapsed or refractory multiple myeloma.
  • Arcellx's lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiple myeloma (r/r MM) in an ongoing Phase 1 study.